Skip to content
HowShorted

Arcturus Therapeutics Holdings Inc. short interest in 2022

In 2022, Arcturus Therapeutics Holdings Inc.'s disclosed short interest ran from 8.55% of shares outstanding on 14 Jan 2022 to 7.18% on 30 Dec 2022, a change of -1.37 percentage points. The year's high was 12.79% on 15 Jun 2022 and its low 7.18% on 30 Dec 2022, averaging 10.09% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.55 days on 29 Jul 2022. Full history: Arcturus Therapeutics Holdings Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Arcturus Therapeutics Holdings Inc. in 2022

2022 in figures

Start of year
8.55% (14 Jan 2022)
End of year
7.18% (30 Dec 2022)
Change
-1.37 pp
High
12.79% (15 Jun 2022)
Low
7.18% (30 Dec 2022)
Average
10.09%
Highest days to cover
7.55 (29 Jul 2022)
SEC filings marked
8

Every report in 2022

Arcturus Therapeutics Holdings Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.55%5.79
31 Jan 202210.02%3.78
15 Feb 20229.82%5.99
28 Feb 20229.36%6.00results (8-K)
15 Mar 20228.96%4.9310-K filed
31 Mar 20229.84%3.91
14 Apr 20229.32%5.89
29 Apr 202211.58%2.74
13 May 202211.70%4.2210-Q filed, results (8-K)
31 May 202212.63%5.52
15 Jun 202212.79%5.18
30 Jun 202211.23%2.95
15 Jul 202210.93%6.11
29 Jul 202210.71%7.55
15 Aug 20229.82%4.9210-Q filed, results (8-K)
31 Aug 20228.44%5.88
15 Sep 20228.56%4.96
30 Sep 20229.37%5.42
14 Oct 20229.92%6.86
31 Oct 202210.86%6.25
15 Nov 20229.83%2.3910-Q filed, results (8-K)
30 Nov 202210.73%7.06
15 Dec 20229.92%4.80
30 Dec 20227.18%3.63

See also: Arcturus Therapeutics Holdings Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.